Click to Share
 
 
  1. Latest News
  2. Submit Press Release
  1. PR Home
  2. Latest News
  3. Feeds
  4. Alerts
  5. Submit Free Press Release
  6. Journalist Account
  7. PRNewswire Distribution

paclitaxel Press Releases

  + XML/RSS  



By IGDRASOL
IGDRASOL will present updates on Cynviloq™, its late clinical stage paclitaxel nanoparticle formulation.

By IGDRASOL
Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for the treatment of cancers.

By IGDRASOL
IGDRASOL today announced that the Company’s Chief Scientific Officer, Kouros Motamed, Ph.D., will present at the Breakthroughs in Basic & Translational Cancer Research Conference, February 25th, 2013, Maui, HI.

By IGDRASOL
IGDRASOL today announced that the Company’s Chief Operating Officer, Larn Hwang, Ph.D., will present at the Tumor Invasion and Metastasis conference, January 21st , 2013, San Diego, CA.

By IGDRASOL
IGDRASOL today announced that Dr. Vuong Trieu, CEO of IGDRASOL, will discuss an overview of the company and the clinical development program for IG-001: a chemical polymer-bound nanoparticle paclitaxel entering phase III clinical testing.

By IGDRASOL
Personalization of paclitaxel therapy by combination of next generation nanoparticle paclitaxel and point-of-care therapeutic drug monitoring and biomarker testing.

All Press Releases

By IGDRASOL
IGDRASOL will present updates on Cynviloq™, its late clinical stage paclitaxel nanoparticle formulation.

By IGDRASOL
Sorrento Therapeutics, Inc. ("STI"; SRNE: OB) today announced that it has signed an exclusive option to acquire IGDRASOL, a private company focused on the development of oncologic agents for the treatment of cancers.

By IGDRASOL
IGDRASOL today announced that the Company’s Chief Scientific Officer, Kouros Motamed, Ph.D., will present at the Breakthroughs in Basic & Translational Cancer Research Conference, February 25th, 2013, Maui, HI.

By IGDRASOL
IGDRASOL today announced that the Company’s Chief Operating Officer, Larn Hwang, Ph.D., will present at the Tumor Invasion and Metastasis conference, January 21st , 2013, San Diego, CA.

By IGDRASOL
IGDRASOL today announced that Dr. Vuong Trieu, CEO of IGDRASOL, will discuss an overview of the company and the clinical development program for IG-001: a chemical polymer-bound nanoparticle paclitaxel entering phase III clinical testing.

By IGDRASOL
Personalization of paclitaxel therapy by combination of next generation nanoparticle paclitaxel and point-of-care therapeutic drug monitoring and biomarker testing.

By Soumyajit
Ajikumar Parayil , an Indian scientist from the Massachusetts Institute of Technology (MIT), has helped Coax E. Coli Bacteria to produce Taxadiene which is a precursor compound for Paclitaxel

By Sahajanand Medical Technologies Pvt. Ltd.
Sahajanand Medical Technologies received positive results of nine month PAINT trials for Drug eluting stents, Infinnium and Supralimus. The results unveiled during plenary session of EuroPCR 2008-Barcelona.



Page updated every 10 minutes


  1. SiteMap
  2. Contact PRLog
  3. Privacy Policy
  4. Terms of Service
  5. Copyright Notice
  6. About
  7. Advertise
Like PRLog?
9K2K1K
Click to Share